Cell Cycle , Cell Death , and Senescence B 1 , a Novel Amonafide Analogue , Overcomes the Resistance Conferred by Bcl-2 in Human Promyelocytic Leukemia HL 60 Cells
Xin Liang,Yufang Xu,Ke Xu,Jianwen Liu,X. Qian
2010-01-01
Abstract:In the course of screening for novel anticancer compounds, B1 [N-(2-(dimethylamino)ethyl)-2aminothiazonaphthalimide], a novel amonafide analogue, was generated as a new anticancer candidate. In the present study, B1 displayed stronger antitumor effects than amonafide in HL60 cells. We further examined whether B1 overcomes the resistance conferred by Bcl-2, as overcoming the resistance conferred by Bcl-2 represents an attractive therapeutic strategy against cancer. Our viability assay showed that B1 overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells. Various apoptosis assessment assays showed that B1 overcomes the resistance conferred by Bcl-2 in HL60 cells by inducing apoptosis. Noticeably, we elucidated the marked downregulation of 14-3-3s protein by B1, indicating that B1 overcomes the resistance conferred by Bcl-2 inHL60 cells via 14-3-3s. The analysis of chromatin immunoprecipitation assay indicated that MBD2 was associated with the methylated 14-3-3s promoter-associated CpG island and thus interfered with transcriptional activity of the methylated promoter. Furthermore, knockdown of MBD2, using siRNA transfection, inhibited B1-induced apoptosis and overcame the resistance conferred by Bcl-2. Accordingly, these data showed the involvement of MBD2 in B1-induced apoptosis and overcoming the resistance conferred by Bcl-2, which suggested that MBD2 might guide the development of future anticancer agents. Mol Cancer Res; 8(12); 1619–32. 2010 AACR. Introduction Many antitumor agents, which interact with different targets, can kill chemosensitive leukemic cells via an apoptotic process (1, 2). Apoptosis is a genetically encoded cell death program characterized by distinct set of morphologic and biochemical changes (3–5). The apoptotic pathway, in general, can be affected by different factors such as the tumor cell type, differentiation status, growth factors, or oncogenes (4). Several genes have been identified as either inducers or repressors of apoptosis. Bcl-2 functions as an antiapoptotic protein (6) and, in general, regulates mitochondrial outer membrane permeabilization and thereby determines the cellular commitment to apoptosis (6–8). The antiapoptotic function of the Bcl-2 protein depends, at least in part, on its ability to dimerize with another member of the Bcl-2 family, Bax (9). Overexpression of Bcl-2 has been reported in a wide variety of cancers. In some preclinical systems, Bcl-2 overexpression has been shown to induce survival, or to restore, the clonogenic potential of malignant progenitor cells (10, 11). On the other hand, antiapoptotic factors, including Bcl-2, impair the ability to achieve remission and cure with chemotherapy, protecting the tumor cells from the apoptotic effects of various antineoplastic agents (12–14). Therefore, overcoming the resistance conferred by antiapoptotic factors such as Bcl-2 represents an attractive therapeutic strategy against leukemia cells (8). Amonafide (Fig. 1), a naphthalimide derivative, although selected for exploratory clinical trials for its potent anticancer activity, has long been challenged by its unpredictable side effects. In the course of screening a series of amonafide analogues, B1 [N-(2-(dimethylamino)ethyl)-2aminothiazonaphthalimide] in this series, that significantly caused damage on DNA and cancer cell growth was identified (15). Moreover, It has been reported that B1 induced cell-cycle arrest and apoptosis in HeLa cells via p53 activation (16). In the present study, we show that B1 induces p53independent apoptosis and overcomes the resistance conferred by Bcl-2 in HL60 (p53-null) cells through MBD2. Materials and Methods Materials B1 and amonafide (>99% pure) were synthesized and provided as described previously (15). A 25 mmol/L of Authors' Affiliation: State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai, PR China Corresponding Author: Jianwen Liu and Xuhong Qian, State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, 268, 130 Meilong Road, Shanghai 200237, PR China. Phone: 86-21-64252044; Fax: 86-21-64252044. E-mail: liujian@ecust.edu.cn; or E-mail: xhqian@ecust.edu.cn doi: 10.1158/1541-7786.MCR-10-0341 2010 American Association for Cancer Research. Molecular Cancer Research www.aacrjournals.org 1619 on June 19, 2017. © 2010 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Published OnlineFirst November 12, 2010; DOI: 10.1158/1541-7786.MCR-10-0341